|
|
|
|
| LEADER |
01000cam a2200265 4500 |
| 001 |
635343509 |
| 003 |
DE-627 |
| 005 |
20240421021103.0 |
| 007 |
tu |
| 008 |
100920s2011 ne ||||| 00| ||eng c |
| 016 |
7 |
|
|a 015594196
|2 UK
|
| 020 |
|
|
|a 9780123849649
|c (hbk.) £91.00
|9 978-0-12-384964-9
|
| 020 |
|
|
|a 0123849640
|c (hbk.) £91.00
|9 0-12-384964-0
|
| 035 |
|
|
|a (DE-627)635343509
|
| 035 |
|
|
|a (DE-576)333504658
|
| 035 |
|
|
|a (DE-599)GBV635343509
|
| 035 |
|
|
|a (OCoLC)731464078
|
| 035 |
|
|
|a (OCoLC)700523498
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 044 |
|
|
|c XA-NL
|c XD-US
|c XA-DE
|
| 082 |
0 |
|
|a 615.19
|q OCLC
|
| 084 |
|
|
|a 15,3
|2 ssgn
|
| 084 |
|
|
|a VX 8560
|q BVB
|2 rvk
|0 (DE-625)rvk/147831:253
|
| 084 |
|
|
|a 58.28
|2 bkl
|
| 245 |
1 |
0 |
|a Challenges in delivery therapeutic genomics and proteomics
|c ed. by Ambikanandan Misra
|
| 250 |
|
|
|a 1. ed.
|
| 264 |
|
1 |
|a Amsterdam
|a Heidelberg [u.a.]
|b Elsevier
|c 2011
|
| 300 |
|
|
|a XIV, 671 S.
|b Ill., graph. Darst.
|c 23 cm
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 490 |
0 |
|
|a Elsevier insights
|
| 500 |
|
|
|a Literaturangaben
|
| 583 |
1 |
|
|a Archivierung/Langzeitarchivierung gewährleistet
|f PEBW
|h DE-31
|x XA-DE-BW
|2 pdager
|5 DE-21
|
| 583 |
1 |
|
|a Archivierung prüfen
|c 20240324
|f DE-4165
|z 1
|2 pdager
|
| 653 |
|
|
|a Protein drugs / Design
|
| 653 |
|
|
|a Pharmaceutical biotechnology
|
| 653 |
|
|
|a Pharmacogenomics
|
| 653 |
|
|
|a Drug delivery systems
|
| 653 |
|
|
|a Protein drugs
|a Design
|
| 689 |
0 |
0 |
|D s
|0 (DE-588)4069491-4
|0 (DE-627)104642904
|0 (DE-576)209176938
|a Biotechnologie
|2 gnd
|
| 689 |
0 |
1 |
|D s
|0 (DE-588)4045699-7
|0 (DE-627)104162406
|0 (DE-576)209066407
|a Pharmazeutische Technologie
|2 gnd
|
| 689 |
0 |
2 |
|D s
|0 (DE-588)4271255-5
|0 (DE-627)104503955
|0 (DE-576)210680172
|a Pharmakogenetik
|2 gnd
|
| 689 |
0 |
3 |
|D s
|0 (DE-588)4190018-2
|0 (DE-627)104492341
|0 (DE-576)210063882
|a Wirkstofffreisetzung
|2 gnd
|
| 689 |
0 |
4 |
|D s
|0 (DE-588)4076388-2
|0 (DE-627)106083007
|0 (DE-576)209201738
|a Proteine
|2 gnd
|
| 689 |
0 |
5 |
|D s
|0 (DE-588)4003115-9
|0 (DE-627)106390619
|0 (DE-576)208850325
|a Arzneimittel
|2 gnd
|
| 689 |
0 |
6 |
|D s
|0 (DE-588)4267580-7
|0 (DE-627)104491531
|0 (DE-576)210649755
|a Therapeutisches System
|2 gnd
|
| 689 |
0 |
|
|5 (DE-627)
|
| 700 |
1 |
|
|a Misra, Ambikanandan
|e hrsg
|4 edt
|
| 776 |
0 |
8 |
|i Online-Ausg.
|t Challenges in delivery of therapeutic genomics and proteomics
|d Oxford : Elsevier, 2010
|h Online Ressource
|w (DE-627)648863271
|w (DE-576)393795497
|z 9780123849649
|z 0123849640
|z 9780123849656
|z 0123849659
|
| 856 |
4 |
2 |
|u http://www.gbv.de/dms/bs/toc/635343509.pdf
|m V:DE-601
|m B:DE-84
|q pdf/application
|x Verlag
|y Inhaltsverzeichnis
|3 Inhaltsverzeichnis
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a ISIL_DE-84
|
| 912 |
|
|
|a SYSFLAG_1
|
| 912 |
|
|
|a GBV_KXP
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 912 |
|
|
|a SSG-OPC-PHA
|
| 912 |
|
|
|a SSG-OPC-DE-84
|
| 912 |
|
|
|a GBV_ILN_69
|
| 912 |
|
|
|a ISIL_DE-9
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a ISIL_DE-21
|
| 912 |
|
|
|a GBV_ILN_2015
|
| 912 |
|
|
|a ISIL_DE-93
|
| 935 |
|
|
|i Blocktest
|
| 936 |
r |
v |
|a VX 8560
|b Allgemeines
|k Chemie und Pharmazie
|k Pharmazeutische Technologie einschl. Biopharmazie
|k Pharmazeutische Technologie allgemein
|k Arzneistoffträger; Liposom Kontrollierte Wirkstofffreisetzung Targeted drug delivery
|k Allgemeines
|0 (DE-627)1271595958
|0 (DE-625)rvk/147831:253
|0 (DE-576)201595958
|
| 936 |
b |
k |
|a 58.28
|j Pharmazeutische Technologie
|0 (DE-627)106417622
|
| 951 |
|
|
|a BO
|
| 953 |
|
|
|2 045F
|a 615.19
|
| 980 |
|
|
|2 20
|1 01
|x 0084
|b 118289495X
|c 00
|f --%%--
|d 2907-0859
|e --%%--
|j --%%--
|y k
|z 05-01-11
|
| 980 |
|
|
|2 69
|1 01
|x 0009
|b 1193796199
|c 00
|f UB 660
|d 660/VX 8550 M678
|e u
|j --%%--
|y z
|z 04-01-11
|
| 980 |
|
|
|2 2001
|1 01
|x DE-21
|b 312014052X
|c 00
|f --%%--
|d 51 A 2099
|e --%%--
|j --%%--
|y l01
|z 25-01-11
|
| 980 |
|
|
|2 2015
|1 01
|x DE-93
|b 3120140627
|c 00
|f --%%--
|d 6C 339
|e --%%--
|j --%%--
|k 1. Ex. in Freihand Vaihingen
|y l01
|z 15-11-10
|
| 983 |
|
|
|2 69
|1 00
|x DE-9
|8 00
|a VX 8550
|
| 984 |
|
|
|2 20
|1 01
|x 0084
|a 84$029070859
|
| 984 |
|
|
|2 69
|1 01
|x 0009
|a 9$08599963
|
| 985 |
|
|
|2 69
|1 01
|x 0009
|a 2010.17204
|
| 998 |
|
|
|2 2001
|1 01
|x DE-21
|0 1103
|f 45
|
| 998 |
|
|
|2 2015
|1 01
|x DE-93
|0 1102
|f 20d
|f 18
|
